Medivir AB (publ) (OTCMKTS:MVRBF – Get Free Report) and Applied Dna Sciences (NASDAQ:BNBX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Medivir AB (publ) and Applied Dna Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medivir AB (publ) | 0 | 0 | 0 | 0 | 0.00 |
| Applied Dna Sciences | 1 | 0 | 0 | 0 | 1.00 |
Institutional & Insider Ownership
23.2% of Medivir AB (publ) shares are held by institutional investors. Comparatively, 22.2% of Applied Dna Sciences shares are held by institutional investors. 6.1% of Applied Dna Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Medivir AB (publ) | N/A | N/A | N/A |
| Applied Dna Sciences | -1,647.25% | -349.95% | -283.96% |
Valuation & Earnings
This table compares Medivir AB (publ) and Applied Dna Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medivir AB (publ) | N/A | N/A | N/A | $32.14 | 0.03 |
| Applied Dna Sciences | $2.09 million | 0.50 | -$15.16 million | ($36.76) | -0.00 |
Medivir AB (publ) has higher earnings, but lower revenue than Applied Dna Sciences. Applied Dna Sciences is trading at a lower price-to-earnings ratio than Medivir AB (publ), indicating that it is currently the more affordable of the two stocks.
Summary
Medivir AB (publ) beats Applied Dna Sciences on 6 of the 9 factors compared between the two stocks.
About Medivir AB (publ)
-logo-1200x675.png){kind=logo}
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
About Applied Dna Sciences
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company’s supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Receive News & Ratings for Medivir AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivir AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
